27
October

08:00 AM BST

Clinical Operations

Name: Clinical Operations & Clinical Trial Supply Chain Strategy Meeting Europe 2026
Start: 2026-02-27T08:00
End: 2026-10-27T18:00
Location: Crowne Plaza, London Docklands

&

Clinical Trial Supply Chain

Strategy Meeting Europe 2026

Advancing Clinical Innovation: Connecting AI, Patients, Operations, and Supply Chains to Accelerate Trial Success.

Crowne Plaza London Docklands

Our Event Starts In

–
days

–
hours

–
minutes

–
seconds

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Clinical Operations Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered. Proventa International’s Clinical Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Clinical Operations professionals from across Europe, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across Europe, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We've partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Our Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our Clinical Operations strategy meeting.

Abhishek Miglani

Head, Enterprise Platform, Senior Director Veeva & Global Clinical Operations Technology, Astellas

Agnese Cattaneo

Chief Medical Officer Angelini Pharma

Alexander Fetkovsky

CEO SanaClis

Alison Walker

Head, Operations Compliance / Global Project Lead TauRx Therapeutics Ltd.

Astrid Scherer

Vice President, Clinical Development and Operations Bayer

Charmaine O’Neill

Vice President, Clinical Operations Vantage Biosciences & Axovia Therapeutics

David Holman

Head, Clinical Program Management 30 Technology

Deirdre Flaherty

Vice President, Development Project Strategy & Clinical Operations Alchemab Therapeutics Ltd

Dr. Apurba Mukherjee

Regional Medical Head, Intercontinental and JAK Regions Ferring Pharmaceuticals

Dr. Tony Lockett

Chief Medical Officer Nevrargenics Ltd.

Eamonn McArdle

Lead Clinical Supply Chain Pharmacist Allergy Therapeutics

Jane Twitchen

Executive Director, Head, Clinical Trial Accelerator Unit Biogen

Jane Twitchen graduated with a BSc in Medical Physics from the University of Exeter, UK and commenced her career with Covance, supporting a number of trials investigating radioisotope image optimisation. Having developed a keen interest in processes and systems, she then joined SAS, where she worked in the Alliances team collaborating with partners such as PWC, McKinsey and Accenture to define and implement solutions for pharmaceutical clients. During her tenure with SAS, Jane was also sponsored to complete her MBA. She proceeded to a number of software and service providers prior to joining Biogen in 2013, initially joining the Global Regulatory Affairs Quality and Operations team and moving to Global Clinical Operations in 2015. In her current role, Jane is Executive Director, Head of Biogen’s Clinical Trial Accelerator Unit and is responsible for delivery of Biogen’s goals for accelerated study start-up cycle time, in addition to embedding innovative operational delivery through the use of technology.

Kamal Amin

Head of Clinical Supplies Management Galderma

Leon Hooftman

Chief Medical Officer Barinthus Biotherapeutics

Leszek Bialecki

Director, Clinical Operations Fresenius-Kabi

Lynette James

Vice President, Supply Chain & External Manufacturing Quell Therapeutics

Pietro Scalfaro

Senior Vice President, Head of Clinical Development Chief Medical Officer ENYO Pharma

Ridwaan Jhetam

Senior Vice President and Head of Worldwide Medical Affairs Hematology Bristol Myers Squibb

Sarah Scorer

Senior Director, Head of Clinical Operations Tangram Therapeutics

Suki Malhi

Vice President, Clinical Operations Grin Therapeutics

First name	Last name	Job title	Company name	Photo URL	Bio Position
Abhishek	Miglani	Head, Enterprise Platform, Senior Director	Veeva & Global Clinical Operations Technology, Astellas	https://proventainternational.com/wp-content/uploads/2025/07/Abhishek-Miglani.jpg	Abhishek Miglani is a visionary leader and industry thought leader advancing patient-centric innovation and access. He blends deep R&D acumen with a relentless focus on transforming healthcare through strategy, partnerships, and digital enablement—shaping the future of the pharmaceutical industry through impactful, ecosystem-wide leadership.
Agnese	Cattaneo	Chief Medical Officer	Angelini Pharma	https://proventainternational.com/wp-content/uploads/2025/04/Agnese-Cattaneo.jpg
Alexander	Fetkovsky	CEO	SanaClis	https://proventainternational.com/wp-content/uploads/2026/09/Alexander-Fetkovsky.jpg	As CEO, Alexander Fetkovsky has overall responsibility for the planning and execution of strategic company initiatives and business partnering, in addition to global operational and financial oversight for multiple clinical programs and clinical trial supply/ warehouse operations. He previously held several C-level positions such as Senior Managing Partner and Member of the Board.
Alison	Walker	Head, Operations Compliance / Global Project Lead	TauRx Therapeutics Ltd.	https://proventainternational.com/wp-content/uploads/2026/06/Alison-Walker.jpg
Astrid	Scherer	Vice President, Clinical Development and Operations	Bayer	https://proventainternational.com/wp-content/uploads/2026/09/Astrid-Scherer.jpg
Charmaine	O’Neill	Vice President, Clinical Operations	Vantage Biosciences & Axovia Therapeutics	https://proventainternational.com/wp-content/uploads/2025/07/Charmaine-ONeill.jpg	Charmaine O’Neill brings over 30 years of diverse experience in Research and Development, currently supporting Axovia Therapeutics and Vantage Biosciences. She was most recently with Gyroscope Therapeutics, a Novartis company, and has held senior roles across pharma and biotech, including GSK, Aimmune Therapeutics, DSPE, PPD, Syneos, and hVivo. Charmaine has led global Phase I–III clinical programs to registration across multiple therapeutic areas, including ophthalmology, virology, diabetes, rare diseases, food allergy, and oncology. She holds BSc (Hons) degrees in Pharmacology and Psychology and is recognized for driving operational excellence in clinical trial delivery across early and late development.
David	Holman	Head, Clinical Program Management	30 Technology	https://proventainternational.com/wp-content/uploads/2026/08/David-Holman.jpg	David Holman, PhD, is a senior clinical development and operations leader with over 20 years of global experience spanning academia, biotechnology, pharma, and CROs. He holds a PhD in Neuroscience from the University of Bristol and has published peer-reviewed research in leading journals. David has held senior leadership roles at 30 Technology, PPD, and Gilead, leading clinical development and operations across respiratory, inflammation/immunology, neurology, and other therapeutic areas. His expertise spans early- to late-stage development, strategic program leadership, and cross-functional team management, with a particular focus on translating scientific strategy into successful clinical development and execution.
Deirdre	Flaherty	Vice President, Development Project Strategy & Clinical Operations	Alchemab Therapeutics Ltd	https://proventainternational.com/wp-content/uploads/2026/08/Deirdre-Flaherty.jpeg	Deirdre Flaherty is the Vice President of Development Project Strategy and Clinical Operations at Alchemab. She works with the product teams to drive the formation of strategy from candidate selection to clinical proof of concept as well as leading the clinical implementation of the strategy; she is simultaneously serving as the Program Lead for the company’s lead asset, ATLX-2847. Deirdre also maintains her own consulting business, LunAr PLPM, where she works with other start-up biotechs to help them in the important period between candidate molecule and clinical proof of concept. She has worked in the industry for almost 30 years with roles in Clinical Development, Portfolio Management, Program leadership and Project Management at Merck KGaA (formerly Merck Serono), GW Pharmaceuticals and Abcam. Deirdre holds a BA from Johns Hopkins University in Baltimore, Maryland, and an MBA from Columbia University in New York, New York.
Dr.	Apurba Mukherjee	Regional Medical Head, Intercontinental and JAK Regions	Ferring Pharmaceuticals	https://proventainternational.com/wp-content/uploads/2026/09/Dr.-Apurba-Mukherjee.jpg
Dr.	Tony Lockett	Chief Medical Officer	Nevrargenics Ltd.	https://proventainternational.com/wp-content/uploads/2026/07/Tony-Lockett.jpg	Dr Tony Lockett is a physician, pharmaceutical medicine specialist and health economist with nearly four decades in clinical drug development. He is Senior Lecturer at King’s College London’s Centre for Pharmaceutical Medicine Research, where he leads the Clinical Drug Development MSc course, Medical Director of the Mark Sommerville Foundation, and Chief Medical Officer of Nevrargenics. Previously CMO at hVIVO, Avecia and Biatmospheric, he holds a PhD in economics and healthcare policy. A long-standing voice in rare disease policy, he chairs the FPM rare diseases expert group and advises the NHS rare disease forum and NICE on trial standards, and co-chairs King’s Research Ethics.
Eamonn	McArdle	Lead Clinical Supply Chain Pharmacist	Allergy Therapeutics	https://proventainternational.com/wp-content/uploads/2026/07/Kamal-Amin.jpg
Jane	Twitchen	Executive Director, Head, Clinical Trial Accelerator Unit	Biogen	https://proventainternational.com/wp-content/uploads/2022/03/Jane-Twitchen.jpg	Jane Twitchen graduated with a BSc in Medical Physics from the University of Exeter, UK and commenced her career with Covance, supporting a number of trials investigating radioisotope image optimisation. Having developed a keen interest in processes and systems, she then joined SAS, where she worked in the Alliances team collaborating with partners such as PWC, McKinsey and Accenture to define and implement solutions for pharmaceutical clients. During her tenure with SAS, Jane was also sponsored to complete her MBA. She proceeded to a number of software and service providers prior to joining Biogen in 2013, initially joining the Global Regulatory Affairs Quality and Operations team and moving to Global Clinical Operations in 2015. In her current role, Jane is Executive Director, Head of Biogen’s Clinical Trial Accelerator Unit and is responsible for delivery of Biogen’s goals for accelerated study start-up cycle time, in addition to embedding innovative operational delivery through the use of technology.
Kamal	Amin	Head of Clinical Supplies Management	Galderma	https://proventainternational.com/wp-content/uploads/2022/06/Kamal-Amin-2.jpg	Kamal has over 15 years of experience in operational and technical roles in end-to-end supply chain (clinical and commercial) with quality focus, including manufacturing, procurement, leadership management in the life sciences, biotechnology, pharmaceutical and device industries. He manages a global team of supply chain specialists, training the next generation of Clinical Supplies Experts. He tries and instills a proactive culture and ‘can-do’ attitude for colleagues and challenge them to volunteer new ideas, resulting in increased operational efficiencies via simplification. He truly believes ‘A team is much more likely to get to an optimized solution than an individual’. Kamal earned a BSc in Medicinal Chemistry, a PhD in Organic Chemistry and an MBA from the American Management Association.
Leon	Hooftman	Chief Medical Officer	Barinthus Biotherapeutics	https://proventainternational.com/wp-content/uploads/2026/07/Leon-Hooftman.jpg
Leszek	Bialecki	Director, Clinical Operations	Fresenius-Kabi	https://proventainternational.com/wp-content/uploads/2026/06/Leszek-Bialecki.jpg
Lynette	James	Vice President, Supply Chain & External Manufacturing	Quell Therapeutics	https://proventainternational.com/wp-content/uploads/2026/06/Lynette-James.jpg
Pietro	Scalfaro	Senior Vice President, Head of Clinical Development Chief Medical Officer	ENYO Pharma	https://proventainternational.com/wp-content/uploads/2026/06/Pietro-Scalfaro.jpg
Ridwaan	Jhetam	Senior Vice President and Head of Worldwide Medical Affairs Hematology	Bristol Myers Squibb	https://proventainternational.com/wp-content/uploads/2026/06/Ridwaan-Jhetam.jpg
Sarah	Scorer	Senior Director, Head of Clinical Operations	Tangram Therapeutics	https://proventainternational.com/wp-content/uploads/2026/07/Sarah-Scorer.jpg
Suki	Malhi	Vice President, Clinical Operations	Grin Therapeutics	https://proventainternational.com/wp-content/uploads/2022/05/avatar.jpg

Abhishek Miglani, Agnese Cattaneo, Alexander Fetkovsky, Alison Walker, Astrid Scherer, Charmaine O’Neill, David Holman, Deirdre Flaherty, Dr. Apurba Mukherjee, Dr. Tony Lockett, Eamonn McArdle, Jane Twitchen, Kamal Amin, Leon Hooftman, Leszek Bialecki, Lynette James, Pietro Scalfaro, Ridwaan Jhetam, Sarah Scorer, Suki Malhi

Our Past Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our Clinical Operations strategy meeting.

Aditya Tallapragada

President AKT Health Inc.

Aditya Tallapragada is the President of AKT Health, bringing over 18+ years of global, multilingual experience across the HealthTech, FinTech, and Life Sciences sectors. As a serial entrepreneur and strategic advisor, he blends deep industry insight with a passion for technology-driven transformation to deliver sustainable, patient-centric solutions. He is known for his leadership in Digital health innovation, offering strategic guidance to startups, enterprises, and blockchain ventures. Aditya’s focus lies in leveraging AI, ML, and blockchain to drive operational efficiency, enhance decision-making, and generate tangible outcomes across healthcare and finance. A recognized speaker and investor, he is also the holder of a patent for an Innovative Information Management System, a breakthrough that simplifies healthcare data workflows and strengthens patient data management. This innovation highlights his dedication to solving realworld challenges with practical, scalable technology. His cross-sector expertise spans market access strategy, global regulatory affairs, econometric modeling, commercial development, and digital transformation, making him a sought-after thought leader in the future of digital health and decentralized ecosystems.

Arijit Patra

Senior Principal Scientist UCB

Dr. Arijit Patra is a Senior Principal Scientist at UCB Biopharma UK and an honorary senior lecturer (associate professor) at the University of Glasgow. He holds a PhD in machine learning for healthcare imaging from the University of Oxford, where he was a Rhodes Scholar (India & Exeter, 2016). Prior to that, he completed a dual degree in mechanical engineering from the Indian Institute of Technology (IIT) at Kharagpur, India, as a Honda Young Engineer & Scientist awardee. He has also been associated with AstraZeneca, Shell, Microsoft Research, and CSIR-South Africa at various points in his career and has been actively involved in the AI4SG (AI for Social Good) community. He has authored several publications around machine learning and medical imaging and is a reviewer for multiple peer-reviewed venues such as NeurIPS, ICML, MICCAI, and several journals. Arijit has been appointed as a Rising Leaders fellow of the Aspen Institute UK, as an International Strategy Forum fellow in 2024, and more recently as an Aspen Ideas Healthcare fellow for 2025.

Bryony Harrop

Vice President, Clinical Development Artios Pharma Ltd

Charmaine O’Neill

Vice President, Clinical Operations Vantage Biosciences & Axovia Therapeutics

Claire Herholdt

Vice President, Clinical Operations Levicept Ltd

David Gillen

Chief Medical Officer Norgine

David is the Chief Medical Officer at Norgine and has been in post since May 2022. David qualified in Medicine, Physiology and Clinical Pharmacology from St. Mary’s Hospital (Imperial College of Science, Technology and Medicine) in 1992. He retained this interest in Pharmaceutical Medicine during his postgraduate training in Cardiology and General Medicine and joined Pfizer Global Research and Development in Sandwich in 1999. After leaving Pfizer David held the role of Head of International Medical Affairs for Gilead Sciences. In 2011 he then moved to work at Celgene where he was Head of Drug Safety and Risk Management for EMEA / APAC for Celgene Ltd. In addition David acted as the QPPV for Celgene’s Pharmacovigilance System in Europe. In 2016 David moved to become Vice President of International Medical Affairs atVertex. In 2019, he was given additional responsibility supervising the whole International Global Development and Medical Affairs function for Vertex. In 2022 David became CMO of Norgine based in London. David has served on the Innovation sub- committee of the ABPI (Initiating the ABPI Real – World data project), represented Industry on the NICE Appeal Panel and was a member of the important RCP working party looking at the relationship between Industry, Academic Medicine and the NHS. David is a visiting Lecturer at Queens University Belfast and Kings College London.

Dr. Annette Janus

Chief Medical Officer Axoltis Pharma

Dr. Loredana Pătru

Regional Medical Director Romania & Medical Lead Trial Optimization - ARENSIA

Dr. Nermeen Varawalla

Chief Medical Officer Scancell Ltd

Dr. Nermeen Varawalla is a business leader in the healthcare & life sciences sectors with expertise in drug development and presently serves as Chief Medical Officer at Scancell Ltd, leading the clinical development of its cancer immunotherapies. Nermeen completed her medical training at the University of Mumbai before receiving a Rhodes Fellowship for her doctorate at Oxford University, following which she worked as an NHS obstetrician and gynecologist. After an MBA at INSEAD, Nermeen transitioned to business by joining Accenture’s Strategy Consulting Practice. Recognizing the opportunity to conduct global clinical trials in India, Nermeen founded a pioneering business, which she sold to PRA Health Sciences (now ICON plc), and proceeded to hold leadership roles in the contract research business. Notably, Nermeen raised private equity financing to build ECCRO, which she exited to join the Intas Pharmaceutical Group. Following this transition, Nermeen has held leadership roles at several biopharmaceutical and medical technology companies, including BTG International plc. until its acquisition by Boston Scientific Corporation, Atlantic Healthcare, and Relief Therapeutics. In addition, she has served as a trustee board member for the Malaria Consortium. Nermeen also serves as Chair of Atorvia Health Technologies with a lead asset for kidney failure, Board Member of the Oxford India Centre at the University of Oxford, and on the Board of Governors at the University of Hertfordshire to provide guidance for the setup of its new medical school. Further, Nermeen is President of the UK INSEAD Alumni Association and the Alumni Association of Somerville College, University of Oxford.

Dr. Rania Al Shami

Chief Business and Strategy Officer PDC - CRO

Farrell Healion

Former Head, Emerging Technology - Senior Director, Global Clinical Solutions AstraZeneca

Kate Lindsell

Vice President, Clinical Operations Zura Bio

Jane Twitchen

Executive Director, Head, Clinical Trial Accelerator Unit Biogen

Lucy Moore

Executive Director, Clinical Data Projects, Clinical Data and Insights AstraZeneca

Mohamed Mostafa

Chief Executive Officer PDC - CRO

Paullette Azar-Tannous

Chief Executive Officer Sonic Clinical Trials

Paullette has over 30 years of leadership in global central laboratory services supporting pharmaceutical and biotech industries across Asia Pacific, Europe, and the US. She leads a highly specialized global team focused on delivering integrated clinical trial solutions with a strong emphasis on operational excellence, innovation, and collaboration. Her areas of expertise span laboratory and quality management systems, systems development, corporate training and development, risk and crisis management, stakeholder engagement, ESG leadership, and corporate and commercial strategy. Paullette has successfully established start-up operations in Australia, Singapore, Belgium, and the US; led large-scale transformation initiatives; shaped operational frameworks; mentored emerging leaders; and fostered collaboration of diverse teams within complex, global organizations. Paullette holds a Bachelor of Biomedical Sciences, a Master of Business Management, and is a recent graduate of the Australian Institute of Company Directors course.

Peter Eley

Manager Clinical Supply Chain Kiniksa Pharmaceuticals

Simon Collins

Executive Director, Head of Oncology Clinical Operations Jazz Pharmaceuticals

Our Agenda

See Which Topics Are Discussed at the Strategy Meeting

09:00 - 10:00

Roundtable Tracks

Emerging Biopharma / Outsourcing / Patient Recruitment
The Lean Clinical Operations Model for Emerging Biopharma

-David Holman
Head, Clinical Program Management
30 Technology

Clinical Technologies / Artificial Intelligence / Decentralized & Hybrid Trials
Digital-Driven Clinical Trial Design for Improved Outcomes

-Abhishek Miglani
Head, Enterprise Platform, Senior Director
Veeva & Global Clinical Operations Technology, Astellas

Early Phase, Global Site Selection & Feasibility Study
Leveraging Human-Enabled AI to Optimize Clinical Trial Sites (Topic TBC)

-Charmaine O’Neill
Vice President, Clinical Operations
Vantage Biosciences & Axovia Therapeutics

Clinical Supplies, Global Networks, Storage & Distribution
Optimizing Supply Chain Performance and Compliance Through Real-Time Visibility

-Alison Walker
Head, Operations Compliance / Global Project Lead
TauRx Therapeutics Ltd.

Clinical Trials In Oncology/ Cns / Cell & Gene Therapies
What Will It Take to Make Cell & Gene Therapy Clinical Trials Faster, More Predictable, and Scalable?

-Lynette James
Vice President, Supply Chain & External Manufacturing
Quell Therapeutics

11:10 - 12:10

Roundtable ( Pharma/Biotech )

Emerging Biopharma / Outsourcing / Patient Recruitment
Decentralized Trials: Reset, Reality Check, and What Actually Works

Clinical Technologies / Artificial Intelligence / Decentralized & Hybrid Trials
Decentralized and Hybrid Trials: What Actually Works in 2026?

Sponsor

Early Phase, Global Site Selection & Feasibility Study
Balancing Risk and Innovation in Early Phase Clinical Trials for New Drug Candidates

Clinical Supplies, Global Networks, Storage & Distribution
Rethinking Clinical Packaging: From Centralized Batching to Agile, On‑Demand Supply in Modern Trials

Clinical Trials In Oncology/ Cns / Cell & Gene Therapies
AI in Oncology Trials: Transforming Data into Actionable Insights

12:15 - 13:15

Roundtable ( Pharma/Biotech )

Emerging Biopharma / Outsourcing / Patient Recruitment
Emerging Biopharma Funding Pressure and Trial Prioritization

-Agnese Cattaneo
Chief Medical Officer
Angelini Pharma

Clinical Technologies / Artificial Intelligence / Decentralized & Hybrid Trials
Monitoring Clinical Trial Progress using KPIs, AI, and Advanced Analytics

-Pietro Scalfaro
Senior Vice President, Head of Clinical Development Chief Medical Officer
ENYO Pharma

Early Phase, Global Site Selection & Feasibility Study
Speed & Efficiency in Start-Up: Reducing Timelines from Feasibility to First‑Patient‑In (FPI)

-Sarah Scorer
Senior Director, Head of Clinical Operations
Tangram Therapeutics

Clinical Supplies, Global Networks, Storage & Distribution
Navigating Regulatory and Logistical Hurdles in Global Clinical Supply Chains (Topic TBC)

-Kamal Amin
Head of Clinical Supplies Management
Galderma

Clinical Trials In Oncology/ Cns / Cell & Gene Therapies
Transforming CNS Drug Development: Faster Decisions, Better Patient Outcomes

-Suki Malhi
Vice President, Clinical Operations
Grin Therapeutics

15:10 - 16:10

Roundtable Tracks

Emerging Biopharma / Outsourcing / Patient Recruitment
AI and the Future of Patient Recruitment (Topic TBC)

-Leon Hooftman
Chief Medical Officer
Barinthus Biotherapeutics

Clinical Technologies / Artificial Intelligence / Decentralized & Hybrid Trials
Decentralized and Hybrid Trials: What Actually Works in 2026? (Topic TBC)

-Dr. Tony Lockett
Chief Medical Officer
Nevrargenics Ltd.

Early Phase, Global Site Selection & Feasibility Study
Maximizing Early-Phase Impact: Reducing Clinical Trial Risk from Day One (Topic TBC)

-Deirdre Flaherty
Vice President, Development Project Strategy & Clinical Operations
Alchemab Therapeutics Ltd

Clinical Supplies, Global Networks, Storage & Distribution
Meeting Supply Chain Challenges in Decentralized Clinical Trials (Topic TBC)

-Leszek Bialecki
Director, Clinical Operations
Fresenius-Kabi

Clinical Trials In Oncology/ Cns / Cell & Gene Therapies
Off-the-Shelf CAR-T: Faster Access, Broader Patient Reach (Topic TBC)

-Ridwaan Jhetam
Senior Vice President and Head of Worldwide Medical Affairs Hematology
Bristol Myers Squibb

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

Clinical Trials Europe

Clinical Operations & Clinical Trial Supply Chain Strategy Meeting Europe 2025

&

Strategy Meeting Europe 2026

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Crowne Plaza London Docklands

Fresh Clinical Operations Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Our Facilitators

Abhishek Miglani

Agnese Cattaneo

Alexander Fetkovsky

Alison Walker

Astrid Scherer

Charmaine O’Neill

David Holman

Deirdre Flaherty

Dr. Apurba Mukherjee

Dr. Tony Lockett

Eamonn McArdle

Jane Twitchen

Kamal Amin

Leon Hooftman

Leszek Bialecki

Lynette James

Pietro Scalfaro

Ridwaan Jhetam

Sarah Scorer

Suki Malhi

Our Past Facilitators

Aditya Tallapragada

Arijit Patra

Bryony Harrop

Charmaine O’Neill

Claire Herholdt

David Gillen

Dr. Annette Janus

Dr. Loredana Pătru

Dr. Nermeen Varawalla

Dr. Rania Al Shami

Farrell Healion

Kate Lindsell

Jane Twitchen

Lucy Moore

Mohamed Mostafa

Paullette Azar-Tannous

Peter Eley

Simon Collins

Our Agenda

See Which Topics Are Discussed at the Strategy Meeting

Breakfast & Registration

Opening Keynote Presentation

Roundtable

Roundtable Tracks

Refreshment Break

Networking / 1-1 Meetings

Networking / 1-1 Meetings

Networking / 1-1 Meetings

Roundtable (Solution)

Roundtable ( Pharma/Biotech )

Sponsor

Roundtable ( Pharma/Biotech )

Roundtable ( Pharma/Biotech )

Networking Lunch

Networking / 1-1 Meetings

Networking / 1-1 Meetings

Afternoon Keynote Presentation

Roundtable ( Pharma/Biotech )

Roundtable Tracks

Crowne Plaza London Docklands